Log In
Print
BCIQ
Print
Print this Print this
 

THR-184

  Manage Alerts
Collapse Summary General Information
Company Thrasos Therapeutics Inc.
DescriptionSmall peptide that selectively activates ALK2 and ALK3
Molecular Target Activin receptor-like kinase 2 (ALK2) (ACVR1) ; Activin receptor-like kinase 3 (ALK3)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationRenal damage
Indication DetailsTreat acute kidney injury (AKI) post-surgery
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today